Photodynamic therapy (PDT) has emerged as one of the important therapeutic options in the management of cancer and other diseases. PDT involves a tumor-localized photosensitizer (PS), which when appropriately illuminated by visible light converts oxygen into cytotoxic reactive oxygen species (ROS), that attack key structural entities within the targeted cells, ultimately resulting in necrosis or apoptosis. Though PDT is a selective modality, it can be further enhanced by combining other targeted therapeutic strategies that include the use of synthetic peptides and nanoparticles for selective delivery of photosensitizers. Another potentially promising strategy is the application of targeted therapeutics that exploit a myriad of critical pathways involved in tumorigenesis and metastasis. Vascular disrupting agents that eradicate tumor vasculature during PDT and anti-angiogenic agents that targets specific molecular pathways and prevent the formation of new blood vessels are novel therapeutic approaches that have been shown to improve treatment outcome. In addition to the well-documented mechanisms of direct cell killing and damage to the tumor vasculature, PDT can also activate the body’s immune response against tumors. Numerous pre-clinical studies and clinical observations have demonstrated the immuno-stimulatory capability of PDT. Herein, we aim to integrate the most important findings with regard to the combination of PDT and other novel targeted therapy approaches, detailing its potential in cancer photomedicine.
Dougherty, T.J.; Gomer, C.J.; Henderson, B.W.; Jori, G.; Kessel, D.; Korbelik, M.; Moan, J.; Peng, Q. Photodynamic therapy. J. Natl. Cancer Inst.？1998, 90, 889–905, doi:10.1093/jnci/90.12.889. 9637138
[3]
Fabris, C.; Valduga, G.; Miotto, G.; Borsetto, L.; Jori, G.; Garbisa, S.; Reddi, E. Photosensitization with zinc (II) phthalocyanine as a switch in the decision between apoptosis and necrosis. Cancer Res.？2001, 61, 7495–7500. 11606385
[4]
Henderson, B.W.; Dougherty, T.J. How does photodynamic therapy work? Photochem. Photobiol.？1992, 55, 145–157. 1603846
Gollnick, S.O.; Brackett, C.M. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol. Res.？2010, 46, 216–226, doi:10.1007/s12026-009-8119-4. 19763892
[7]
Kalyn, R. Overview of targeted therapies in oncology. J. Oncol. Pharm. Pract.？2007, 13, 199–205, doi:10.1177/1078155207080804. 18045779
[8]
Josefsen, L.B.; Boyle, R.W. Photodynamic therapy: novel third-generation photosensitizers one step closer? Br. J. Pharmacol？2008, 154, 1–3, doi:10.1038/bjp.2008.98. 18362894
[9]
Sharman, W.M.; van Lier, J.E.; Allen, C.M. Targeted photodynamic therapy via receptor mediated delivery systems. Adv. Drug Deliv. Rev.？2004, 56, 53–76, doi:10.1016/j.addr.2003.08.015. 14706445
[10]
Bechet, D.; Couleaud, P.; Frochot, C.; Viriot, M.L.; Guillemin, F.; Barberi-Heyob, M. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol.？2008, 26, 612–621, doi:10.1016/j.tibtech.2008.07.007. 18804298
[11]
Abels, C. Targeting of the vascular system of solid tumours by photodynamic therapy (PDT). Photochem. Photobiol. Sci.？2004, 3, 765–771, doi:10.1039/b314241h. 15295633
[12]
Kamrava, M.; Bernstein, M.B.; Camphausen, K.; Hodge, J.W. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? Mo. Biosyst.？2009, 5, 1262–1270, doi:10.1039/b911313b.
[13]
Bhuvaneswari, R.; Gan, Y.Y.; Soo, K.C.; Olivo, M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol. Cancer？2009, 8, 94. 19878607
[14]
Rahimipour, S.; Ben-Aroya, N.; Ziv, K.; Chen, A.; Fridkin, M.; Koch, Y. Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues. J. Med. Chem.？2003, 46, 3965–3974, doi:10.1021/jm020535y. 12954050
[15]
De Luca, S.; Tesauro, D.; Di Lello, P.; Fattorusso, R.; Saviano, M.; Pedone, C.; Morelli, G. Synthesis and solution characterization of a porphyrin-CCK8 conjugate. J. Pept. Sci.？2001, 7, 386–394, doi:10.1002/psc.337. 11495499
[16]
Renno, R.Z.; Terada, Y.; Haddadin, M.J.; Michaud, N.A.; Gragoudas, E.S.; Miller, J.W. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch. Ophthalmol.？2004, 122, 1002–1011, doi:10.1001/archopht.122.7.1002. 15249365
[17]
Ichikawa, K.; Hikita, T.; Maeda, N.; Yonezawa, S.; Takeuchi, Y.; Asai, T.; Namba, Y.; Oku, N. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim. Biophys. Acta？2005, 1669, 69–74, doi:10.1016/j.bbamem.2005.02.003. 15843001
[18]
Oku, N.; Ishii, T. Antiangiogenic photodynamic therapy with targeted liposomes. Methods Enzymol.？2009, 465, 313–330. 19913174
[19]
Hamblin, M.R.; Miller, J.L.; Hasan, T. Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res.？1996, 56, 5205–5210. 8912858
[20]
Krinick, N.L.; Sun, Y.; Joyner, D.; Spikes, J.D.; Straight, R.C.; Kopecek, J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomater. Sci. Polym. Ed.？1994, 5, 303–324, doi:10.1163/156856294X00040. 8025029
[21]
Chaleix, V.; Sol, V.; Huang, Y.; Guilloton, M.; Granet, R.; Blais, J.-C.; Krausz, P. RGD Porphyrin Conjugates: Synthesis and Potential Application in Photodynamic Therapy. Eur. J. Org. Chem.？2003, 8, 1486–1493, doi:10.1002/ejoc.200390208.
[22]
Chaleix, V.; Sol, V.; Guilloton, M.; Granet, R.; Krausz, P. Efficient synthesis of RGD containing cyclic peptide–porphyrin conjugates by ring-closing metathesis on solid support. Tetrahedron Lett.？2004, 45, 5295–5299, doi:10.1016/j.tetlet.2004.05.004.
[23]
Frochot, C.; Di Stasio, B.; Vanderesse, R.; Belgy, M.J.; Dodeller, M.; Guillemin, F.; Viriot, M.L.; Barberi-Heyob, M. Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity. Bioorg. Chem.？2007, 35, 205–220, doi:10.1016/j.bioorg.2006.11.005. 17223161
[24]
Conway, C.L.; Walker, I.; Bell, A.; Roberts, D.J.; Brown, S.B.; Vernon, D.I. In vivo and in vitro characterisation of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy. Photochem. Photobiol. Sci.？2008, 7, 290–298, doi:10.1039/b715141a. 18389145
[25]
Brooks, P.C.; Clark, R.A.; Cheresh, D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science？1994, 264, 569–571, doi:10.1126/science.7512751. 7512751
[26]
Haubner, R.; Wester, H.J.; Weber, W.A.; Mang, C.; Ziegler, S.I.; Goodman, S.L.; Senekowitsch-Schmidtke, R.; Kessler, H.; Schwaiger, M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res.？2001, 61, 1781–1785. 11280722
[27]
Assa-Munt, N.; Jia, X.; Laakkonen, P.; Ruoslahti, E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry？2001, 40, 2373–2378, doi:10.1021/bi002101f. 11327857
[28]
Sheldon, K.; Liu, D.; Ferguson, J.; Gariepy, J. Loligomers: design of de novo peptide-based intracellular vehicles. Proc. Natl. Acad. Sci. USA？1995, 92, 2056–2060, doi:10.1073/pnas.92.6.2056. 7892224
[29]
Singh, D.; Kiarash, R.; Kawamura, K.; LaCasse, E.C.; Gariepy, J. Penetration and intracellular routing of nucleus-directed peptide-based shuttles (loligomers) in eukaryotic cells. Biochemistry？1998, 37, 5798–5809, doi:10.1021/bi972762l. 9558313
[30]
Singh, D.; Bisland, S.K.; Kawamura, K.; Gariepy, J. Peptide-based intracellular shuttle able to facilitate gene transfer in mammalian cells. Bioconjug. Chem.？1999, 10, 745–754, doi:10.1021/bc980131d. 10502339
[31]
Dozzo, P.; Koo, M.S.; Berger, S.; Forte, T.M.; Kahl, S.B. Synthesis, characterization, and plasma lipoprotein association of a nucleus-targeted boronated porphyrin. J. Med. Chem.？2005, 48, 357–359, doi:10.1021/jm049277q. 15658849
[32]
Maletinska, L.; Blakely, E.A.; Bjornstad, K.A.; Deen, D.F.; Knoff, L.J.; Forte, T.M. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res.？2000, 60, 2300–2303. 10786698
[33]
van Hell, A.J.; Costa, C.I.; Flesch, F.M.; Sutter, M.; Jiskoot, W.; Crommelin, D.J.; Hennink, W.E.; Mastrobattista, E. Self-assembly of recombinant amphiphilic oligopeptides into vesicles. Biomacromolecules？2007, 8, 2753–2761, doi:10.1021/bm0704267. 17696394
[34]
van Hell, A.J.; Fretz, M.M.; Crommelin, D.J.; Hennink, W.E.; Mastrobattista, E. Peptide nanocarriers for intracellular delivery of photosensitizers. J. Control. Release？2009, 141, 347–353, doi:10.1016/j.jconrel.2009.09.012. 19766680
[35]
Tsay, J.M.; Trzoss, M.; Shi, L.; Kong, X.; Selke, M.; Jung, M.E.; Weiss, S. Singlet oxygen production by Peptide-coated quantum dot-photosensitizer conjugates. J. Am. Chem. Soc.？2007, 129, 6865–6871, doi:10.1021/ja070713i. 17477530
[36]
Duska, L.R.; Hamblin, M.R.; Bamberg, M.P.; Hasan, T. Biodistribution of charged F(ab')2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br. J. Cancer？1997, 75, 837–844, doi:10.1038/bjc.1997.149. 9062404
[37]
Ichikawa, K.; Hikita, T.; Maeda, N.; Takeuchi, Y.; Namba, Y.; Oku, N. PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy. Biol. Pharm. Bull.？2004, 27, 443–444, doi:10.1248/bpb.27.443. 14993821
Konan, Y.N.; Gurny, R.; Allemann, E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B？2002, 66, 89–106, doi:10.1016/S1011-1344(01)00267-6. 11897509
[43]
Florence, A.T.; Hussain, N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv. Drug Deliv. Rev.？2001, 50 Suppl. 1, S69–S89, doi:10.1016/S0169-409X(01)00184-3. 11576696
[44]
Oba, T. Photosensitizer Nanoparticles for Photodynamic Therapy. Current Bioactive Compounds？2007, 3, 239–251, doi:10.2174/157340707783220248.
[45]
Lee, S.J.; Park, K.; Oh, Y.K.; Kwon, S.H.; Her, S.; Kim, I.S.; Choi, K.; Kim, H.; Lee, S.G.; Kim, K.; Kwon, I.C. Tumor specificity and therapeutic efficacy of photosensitizer-encapsulated glycol chitosan-based nanoparticles in tumor-bearing mice. Biomaterials？2009, 30, 2929–2939, doi:10.1016/j.biomaterials.2009.01.058. 19254811
[46]
Zeisser-Labouebe, M.; Delie, F.; Gurny, R.; Lange, N. Benefits of nanoencapsulation for the hypercin-mediated photodetection of ovarian micrometastases. Eur. J. Pharm. Biopharm.？2009, 71, 207–213, doi:10.1016/j.ejpb.2008.10.005. 18977296
[47]
Roy, I.; Ohulchanskyy, T.Y.; Pudavar, H.E.; Bergey, E.J.; Oseroff, A.R.; Morgan, J.; Dougherty, T.J.; Prasad, P.N. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J. Am. Chem. Soc.？2003, 125, 7860–7865, doi:10.1021/ja0343095. 12823004
[48]
Wieder, M.E.; Hone, D.C.; Cook, M.J.; Handsley, M.M.; Gavrilovic, J.; Russell, D.A. Intracellular photodynamic therapy with photosensitizer-nanoparticle conjugates: cancer therapy using a 'Trojan horse'. Photochem. Photobiol. Sci.？2006, 5, 727–734, doi:10.1039/b602830f. 16886087
[49]
Yaghini, E.; Seifalian, A.M.; MacRobert, A.J. Quantum dots and their potential biomedical applications in photosensitization for photodynamic therapy. Nanomedicine (Lond)？2009, 4, 353–363, doi:10.2217/nnm.09.9. 19331542
[50]
Hone, D.C.; Walker, P.I.; Evans-Gowing, R.; FitzGerald, S.; Beeby, A.; Chambrier, I.; Cook, M.J.; Russell, D.A. Generation of cytotoxic singlet oxygen via phthalocyanine-stabilized gold nanoparticles: A potential delivery vehicle for photodynamic therapy. Langmuir？2002, 18, 2985–2987, doi:10.1021/la0256230.
[51]
Chen, W.; Zhang, J. Using nanoparticles to enable simultaneous radiation and photodynamic therapies for cancer treatment. J. Nanosci. Nanotechnol.？2006, 6, 1159–1166, doi:10.1166/jnn.2006.327. 16736782
[52]
Samia, A.C.; Chen, X.; Burda, C. Semiconductor quantum dots for photodynamic therapy. J. Am. Chem. Soc.？2003, 125, 15736–15737, doi:10.1021/ja0386905. 14677951
[53]
Ma, J.; Chen, J.Y.; Idowu, M.; Nyokong, T. Generation of singlet oxygen via the composites of water-soluble thiol-capped CdTe quantum dots-sulfonated aluminum phthalocyanines. J. Phys. Chem. B？2008, 112, 4465–4469, doi:10.1021/jp711537j. 18363400
[54]
Gao, D.; Agayan, R.R.; Xu, H.; Philbert, M.A.; Kopelman, R. Nanoparticles for two-photon photodynamic therapy in living cells. Nano Lett.？2006, 6, 2383–2386, doi:10.1021/nl0617179. 17090062
Zhang, P.; Steelant, W.; Kumar, M.; Scholfield, M. Versatile photosensitizers for photodynamic therapy at infrared excitation. J. Am. Chem. Soc.？2007, 129, 4526–4527, doi:10.1021/ja0700707. 17385866
[57]
Heer, S.; Kompe, K.; Gudel, H.U.; Haase, M. Highly efficient multicolour upconversion emission in transparent colloids of lanthanide doped NaYF4 nanocrystals. Adv. Mater.？2004, 16, 2102–2105, doi:10.1002/adma.200400772.
[58]
Siemann, D.W.; Bibby, M.C.; Dark, G.G.; Dicker, A.P.; Eskens, F.A.; Horsman, M.R.; Marme, D.; Lorusso, P.M. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res.？2005, 11, 416–420. 15701823
[59]
Trachtenberg, J.; Weersink, R.A.; Davidson, S.R.; Haider, M.A.; Bogaards, A.; Gertner, M.R.; Evans, A.; Scherz, A.; Savard, J.; Chin, J.L.; Wilson, B.C.; Elhilali, M. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int.？2008, 102, 556–562, doi:10.1111/j.1464-410X.2008.07753.x. 18494829
[60]
Chen, B.; Pogue, B.W.; Zhou, X.; O'Hara, J.A.; Solban, N.; Demidenko, E.; Hoopes, P.J.; Hasan, T. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin. Cancer Res.？2005, 11, 720–727. 15701861
[61]
Krammer, B. Vascular effects of photodynamic therapy. Anticancer Res.？2001, 21, 4271–4277. 11908681
[62]
Chen, B.; Pogue, B.W.; Hoopes, P.J.; Hasan, T. Vascular and cellular targeting for photodynamic therapy. Crit. Rev. Eukaryot. Gene Expr.？2006, 16, 279–305, doi:10.1615/CritRevEukarGeneExpr.v16.i4.10. 17206921
[63]
Star, W.M.; Marijnissen, H.P.; van den Berg-Blok, A.E.; Versteeg, J.A.; Franken, K.A.; Reinhold, H.S. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res.？1986, 46, 2532–2540. 3697992
Chen, B.; Crane, C.; He, C.; Gondek, D.; Agharkar, P.; Savellano, M.D.; Hoopes, P.J.; Pogue, B.W. Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy. Int. J. Cancer？2008, 123, 695–701, doi:10.1002/ijc.23538. 18498134
[66]
Chen, B.; Pogue, B.W.; Luna, J.M.; Hardman, R.L.; Hoopes, P.J.; Hasan, T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin. Cancer Res.？2006, 12, 917–923, doi:10.1158/1078-0432.CCR-05-1673. 16467106
[67]
Fingar, V.H.; Wieman, T.J.; Wiehle, S.A.; Cerrito, P.B. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res.？1992, 52, 4914–4921. 1387584
[68]
Fingar, V.H.; Wieman, T.J.; Haydon, P.S. The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin. Photochem. Photobiol.？1997, 66, 513–517, doi:10.1111/j.1751-1097.1997.tb03182.x. 9337624
[69]
Fingar, V.H.; Wieman, T.J.; Karavolos, P.S.; Doak, K.W.; Ouellet, R.; van Lier, J.E. The effects of photodynamic therapy using differently substituted zinc phthalocyanines on vessel constriction, vessel leakage and tumor response. Photochem. Photobiol.？1993, 58, 251–258, doi:10.1111/j.1751-1097.1993.tb09557.x. 8415918
[70]
He, C.; Babasola, F.; Chen, B. Combination of vascular targeting PDT with combretastatin A4 phosphate. Proc. SPIE？2009, 7380, 738032.
[71]
Byrne, A.T.; O'Connor, A.E.; Hall, M.; Murtagh, J.; O'Neill, K.; Curran, K.M.; Mongrain, K.; Rousseau, J.A.; Lecomte, R.; McGee, S.; Callanan, J.J.; O'Shea, D.F.; Gallagher, W.M. Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. Br. J. Cancer？2009, 101, 1565–1573, doi:10.1038/sj.bjc.6605247. 19826417
[72]
Seshadri, M.; Spernyak, J.A.; Mazurchuk, R.; Camacho, S.H.; Oseroff, A.R.; Cheney, R.T.; Bellnier, D.A. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Clin. Cancer Res.？2005, 11, 4241–4250, doi:10.1158/1078-0432.CCR-04-2703. 15930363
[73]
Dolmans, D.E.; Kadambi, A.; Hill, J.S.; Waters, C.A.; Robinson, B.C.; Walker, J.P.; Fukumura, D.; Jain, R.K. Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res.？2002, 62, 2151–2156. 11929837
[74]
Chen, B.; Roskams, T.; de Witte, P.A. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem. Photobiol.？2002, 76, 509–513, doi:10.1562/0031-8655(2002)076<0509:ATEBHM>2.0.CO;2. 12462645
[75]
Bhuvaneswari, R.; Gan, Y.Y.; Soo, K.C.; Olivo, M. The effect of photodynamic therapy on tumor angiogenesis. Cell. Mol. Life Sci.？2009, 66, 2275–2283, doi:10.1007/s00018-009-0016-4. 19333552
[76]
Ferrario, A.; Gomer, C.J. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J. Environ. Pathol. Toxicol. Oncol.？2006, 25, 251–259, doi:10.1615/JEnvironPatholToxicolOncol.v25.i1-2.160. 16566722
[77]
Bhuvaneswari, R.; Yuen, G.Y.; Chee, S.K.; Olivo, M. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. Photochem. Photobiol. Sci.？2007, 6, 1275–1283, doi:10.1039/b705763f. 18046482
[78]
Kosharskyy, B.; Solban, N.; Chang, S.K.; Rizvi, I.; Chang, Y.; Hasan, T. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res.？2006, 66, 10953–10958, doi:10.1158/0008-5472.CAN-06-1793. 17108133
[79]
Bhuvaneswari, R.; Gan, Y.Y.; Lucky, S.S.; Chin, W.W.; Ali, S.M.; Soo, K.C.; Olivo, M. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol. Cancer？2008, 7, 56, doi:10.1186/1476-4598-7-56. 18549507
[80]
Zwick, E.; Bange, J.; Ullrich, A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr. Relat. Cancer？2001, 8, 161–173, doi:10.1677/erc.0.0080161. 11566607
[81]
Zhou, Q.; Olivo, M.; Lye, K.Y.; Moore, S.; Sharma, A.; Chowbay, B. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother. Pharmacol.？2005, 56, 569–577, doi:10.1007/s00280-005-1017-0. 16001166
[82]
Dimitroff, C.J.; Klohs, W.; Sharma, A.; Pera, P.; Driscoll, D.; Veith, J.; Steinkampf, R.; Schroeder, M.; Klutchko, S.; Sumlin, A.; Henderson, B.; Dougherty, T.J.; Bernacki, R.J. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest. New Drugs？1999, 17, 121–135, doi:10.1023/A:1006367032156. 10638483
[83]
Ferrario, A.; Fisher, A.M.; Rucker, N.; Gomer, C.J. Celecoxib and NS-398 enhance photodynamic therapy by increasing N vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res.？2005, 65, 9473–9478, doi:10.1158/0008-5472.CAN-05-1659. 16230411
[84]
Makowski, M.; Grzela, T.; Niderla, J.; M, L.A.; Mroz, P.; Kopee, M.; Legat, M.; Strusinska, K.; Koziak, K.; Nowis, D.; Mrowka, P.; Wasik, M.; Jakobisiak, M.; Golab, J. Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin. Cancer Res.？2003, 9, 5417–5422. 14614028
[85]
Yee, K.K.; Soo, K.C.; Olivo, M. Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. Int. J. Mol. Med.？2005, 16, 993–1002. 16273277
[86]
Harvey, E.H.; Webber, J.; Kessel, D.; Fromm, D. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398. Am. J. Surg.？2005, 189, 302–305, doi:10.1016/j.amjsurg.2004.11.016. 15792755
[87]
Hendrickx, N.; Volanti, C.; Moens, U.; Seternes, O.M.; de Witte, P.; Vandenheede, J.R.; Piette, J.; Agostinis, P. Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J. Biol. Chem.？2003, 278, 52231–52239, doi:10.1074/jbc.M307591200. 14557269
[88]
Nicholson, R.I.; Gee, J.M.; Harper, M.E. EGFR and cancer prognosis. Eur. J. Cancer？2001, 37 Suppl 4, S9–S15, doi:10.1016/S0959-8049(01)00231-3. 11597399
[89]
Koon, H.K.; Chan, P.S.; Wong, R.N.; Wu, Z.G.; Lung, M.L.; Chang, C.K.; Mak, N.K. Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. J. Cell. Biochem.？2009, 108, 1356–1363, doi:10.1002/jcb.22366. 19816982
[90]
Weyergang, A.; Selbo, P.K.; Berg, K. Y1068 phosphorylation is the most sensitive target of disulfonated tetraphenylporphyrin-based photodynamic therapy on epidermal growth factor receptor. Biochem. Pharmacol.？2007, 74, 226–235, doi:10.1016/j.bcp.2007.04.018. 17531956
[91]
Soukos, N.S.; Hamblin, M.R.; Keel, S.; Fabian, R.L.; Deutsch, T.F.; Hasan, T. Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res.？2001, 61, 4490–4496. 11389080
[92]
del Carmen, M.G.; Rizvi, I.; Chang, Y.; Moor, A.C.; Oliva, E.; Sherwood, M.; Pogue, B.; Hasan, T. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J. Natl. Cancer Inst.？2005, 97, 1516–1524, doi:10.1093/jnci/dji314. 16234565
[93]
Ahmad, N.; Kalka, K.; Mukhtar, H. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene？2001, 20, 2314–2317, doi:10.1038/sj.onc.1204313. 11402326
[94]
Korbelik, M.; Krosl, G.; Krosl, J.; Dougherty, G.J. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res.？1996, 56, 5647–5652. 8971170
[95]
Korbelik, M.; Dougherty, G.J. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res.？1999, 59, 1941–1946. 10213504
[96]
Gollnick, S.O.; Owczarczak, B.; Maier, P. Photodynamic therapy and anti-tumor immunity. Lasers Surg. Med.？2006, 38, 509–515, doi:10.1002/lsm.20362. 16788921
[97]
Kabingu, E.; Vaughan, L.; Owczarczak, B.; Ramsey, K.D.; Gollnick, S.O. CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br. J. Cancer？2007, 96, 1839–1848, doi:10.1038/sj.bjc.6603792. 17505510
[98]
Gollnick, S.O.; Vaughan, L.; Henderson, B.W. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res.？2002, 62, 1604–1608. 11912128
[99]
Korbelik, M.; Stott, B.; Sun, J. Photodynamic therapy-generated vaccines: relevance of tumour cell death expression. Br. J. Cancer？2007, 97, 1381–1387, doi:10.1038/sj.bjc.6604059. 17971767
[100]
Abdel-Hady, E.S.; Martin-Hirsch, P.; Duggan-Keen, M.; Stern, P.L.; Moore, J.V.; Corbitt, G.; Kitchener, H.C.; Hampson, I.N. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res.？2001, 61, 192–196. 11196160
Seshadri, M.; Bellnier, D.A.; Vaughan, L.A.; Spernyak, J.A.; Mazurchuk, R.; Foster, T.H.; Henderson, B.W. Light delivery over extended time periods enhances the effectiveness of photodynamic therapy. Clin. Cancer Res.？2008, 14, 2796–2805, doi:10.1158/1078-0432.CCR-07-4705. 18451247
[111]
Kousis, P.C.; Henderson, B.W.; Maier, P.G.; Gollnick, S.O. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res.？2007, 67, 10501–10510, doi:10.1158/0008-5472.CAN-07-1778. 17974994
